Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Christina Gesse"'
Autor:
Kevin Schifferli, Gordon Moody, Karma Dacosta, Nina Chu, Ryan Gilbreth, Lori Clarke, Christina Gesse, Letizia Giardino, Cui Chen, Erin Sult, Noel Monks, Ravinder Tammali, Jon Chesebrough, Jessica Tong, Xiao-Tao Yao, Kapil Vashisht
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/4c51e28240674a9e93fe3715949db0c1
Autor:
Maria Letizia Giardino Torchia, Ryan Gilbreth, Ashley Merlino, Erin Sult, Noel Monks, Jon Chesebrough, Ravinder Tammali, Nina Chu, Jessica Tong, John Meekin, Kevin Schifferli, Kapil Vashisht, Karma DaCosta, Lori Clarke, Christina Gesse, Xiao-Tao Yao, Courtney Bridges, Gordon Moody
Publikováno v:
Cytotherapy. 24(7)
Chimeric antigen receptor (CAR) T cell therapy has yielded impressive clinical results in hematological malignancies and is a promising approach for solid tumor treatment. However, toxicity, including cytokine-release syndrome (CRS) and neurotoxicity
Autor:
Nina J. Chu, Michael G. Overstreet, Ryan Gilbreth, Lori Clarke, Christina Gesse, Eric Tu, Gordon Moody, Maria Letizia Giardino Torchia
Publikováno v:
Cancer Research. 82:2837-2837
Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and the third leading cause of cancer-related death worldwide. Immune checkpoint inhibitors have been recently approved in the first-line setting, however only 20-30%
Autor:
Lori A. Clarke, Michael G. Overstreet, Eric Tu, Christina Gesse, Nina Chu, Letizia Giardino, Gordon Moody, Ryan Gilbreth
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Chimeric antigen receptors (CARs) are engineered synthetic receptors that reprogram T cell specificity and function against a given antigen. Autologous CAR-T cell therapy has demonstrated potent efficacy against various hematological malig
Autor:
Nina Chu, Kevin Schifferli, Gordon Moody, Christina Gesse, Jon Chesebrough, Noel R. Monks, Letizia Giardino, Lori A. Clarke, Xiao-Tao Yao, Erin Sult, Kapil Vashisht, Karma Dacosta, Cui Chen, Jessica Tong, Ravinder Tammali, Ryan Gilbreth
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Chimeric antigen receptor (CAR)-T therapy has yielded impressive clinical results in hematological malignancies and it is a promising approach for solid tumor treatment. However, toxicity, including on-target off-tumor antigen binding, is